MCID: PPL002
MIFTS: 51

Papillary Carcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Papillary Carcinoma

Aliases & Descriptions for Papillary Carcinoma:

Name: Papillary Carcinoma 12 14
Carcinoma, Papillary 42 69
Papillary Carcinoma Nos 12
Carcinoma Papillary 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3113
MeSH 42 D002291
NCIt 47 C2927
SNOMED-CT 64 189562005 25910003
UMLS 69 C0007133

Summaries for Papillary Carcinoma

Disease Ontology : 12 A carcinoma that is derives from epithelial cells with finger like projections.

MalaCards based summary : Papillary Carcinoma, also known as carcinoma, papillary, is related to struma ovarii and peritoneal serous papillary adenocarcinoma. An important gene associated with Papillary Carcinoma is TG (Thyroglobulin), and among its related pathways/superpathways are Glioma and Development HGF signaling pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, breast and lymph node, and related phenotypes are Decreased viability and cellular

Related Diseases for Papillary Carcinoma

Diseases related to Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 285)
id Related Disease Score Top Affiliating Genes
1 struma ovarii 30.0 KRT20 MUC1 PGR
2 peritoneal serous papillary adenocarcinoma 29.6 CALCA CDH1 KRT19 LGALS3 NKX2-1 PAX8
3 chondroblastoma 29.5 KRT20 MUC1 NKX2-1
4 gastrinoma 29.0 CALCA NKX2-1 RET TG TSHR
5 peritoneal mesothelioma 27.5 BRAF CALCA CDH1 KRT19 LGALS3 MET
6 breast papillary carcinoma 12.0
7 tall cell variant papillary carcinoma 11.9
8 primary peritoneal serous/papillary carcinoma 11.9
9 ovary papillary carcinoma 11.9
10 gallbladder papillary carcinoma 11.8
11 papillary carcinoma of the cervix uteri 11.8
12 bladder urothelial papillary carcinoma 11.8
13 columnar cell variant papillary carcinoma 11.8
14 kidney pelvis papillary carcinoma 11.8
15 familial renal papillary carcinoma 11.8
16 primary peritoneal carcinoma 11.7
17 penis papillary carcinoma 11.7
18 papillary carcinoma of the corpus uteri 11.7
19 renal cell carcinoma 11.2
20 thyroid cancer, monmedullary, 1 11.0
21 papillary serous adenocarcinoma 10.9
22 renal cell carcinoma, papillary 10.9
23 papillary squamous carcinoma 10.9
24 thyroid cancer, nonmedullary, 2 10.9
25 thyroiditis 10.8
26 multicentric papillary thyroid carcinoma 10.7
27 papillary thymic adenocarcinoma 10.7
28 nonencapsulated sclerosing carcinoma 10.7
29 mouth disease 10.4 ERBB2 PGR
30 trigonocephaly, nonsyndromic 10.3 BRAF ERBB2 RET
31 hypogonadotropic hypogonadism 16 with or without anosmia 10.3 HGF MET
32 endophthalmitis 10.3 CALCA TG
33 autosomal dominant nonsyndromic deafness 6 10.3 HGF MET
34 immunodeficiency due to a late component of complement deficiency 10.3 ERBB2 PGR RET
35 cowden syndrome 3 10.3 CALCA RET TG
36 spastic diplegia infantile type 10.3 BRAF ERBB2 MUC1
37 nasal cavity adenocarcinoma 10.3 ERBB2 MUC1 TG
38 rectum kaposi's sarcoma 10.3 HGF MET RET
39 lacrimal gland mucoepidermoid carcinoma 10.3 MUC1 PGR
40 porokeratosis 10.2 MUC1 NKX2-1 PGR
41 bone marrow cancer 10.2 MUC1 NKX2-1 PGR
42 angiolipomatosis, familial 10.2 ERBB2 KRT20 MUC1
43 chromophil adenoma of the kidney 10.2 KRT20 NKX2-1 TG
44 urinary tract papillary transitional cell benign neoplasm 10.2 CALCA NKX2-1 RET
45 adenoma 10.2
46 childhood teratocarcinoma of the testis 10.2 CALCA RET TG
47 bartholin's gland benign neoplasm 10.2 ESR1 PGR
48 papillary adenofibroma 10.2 KRT19 KRT20 MUC1
49 breast pericanalicular fibroadenoma 10.2 KRT20 NKX2-1 PGR
50 mesenchymoma 10.2 KRT20 MUC1 PGR

Graphical network of the top 20 diseases related to Papillary Carcinoma:



Diseases related to Papillary Carcinoma

Symptoms & Phenotypes for Papillary Carcinoma

GenomeRNAi Phenotypes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.55 BRAF
2 Decreased viability GR00221-A-1 9.55 ESR1 HGF RET
3 Decreased viability GR00221-A-2 9.55 ESR1 HGF RET
4 Decreased viability GR00221-A-3 9.55 ERBB2
5 Decreased viability GR00221-A-4 9.55 ERBB2 ESR1 HGF RET BRAF
6 Decreased viability GR00231-A 9.55 RET
7 Decreased viability GR00301-A 9.55 RET BRAF
8 Decreased viability GR00381-A-1 9.55 BRAF

MGI Mouse Phenotypes related to Papillary Carcinoma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 BRAF CDH1 ERBB2 ESR1 HGF KRT19
2 cardiovascular system MP:0005385 10.34 NKX2-1 PAX8 PGR RET BRAF CDH1
3 endocrine/exocrine gland MP:0005379 10.32 BRAF CDH1 ERBB2 ESR1 KRT19 MET
4 homeostasis/metabolism MP:0005376 10.32 CDH1 ERBB2 ESR1 LGALS3 MET NCOA4
5 growth/size/body region MP:0005378 10.31 BRAF CDH1 ERBB2 ESR1 HGF KRT19
6 mortality/aging MP:0010768 10.28 TPO TSHR BRAF CDH1 ERBB2 ESR1
7 embryo MP:0005380 10.22 BRAF CDH1 ERBB2 ESR1 HGF KRT19
8 digestive/alimentary MP:0005381 10.19 BRAF CDH1 ERBB2 ESR1 KRT19 LGALS3
9 neoplasm MP:0002006 10.14 KRT19 LGALS3 MET NKX2-1 PGR RET
10 nervous system MP:0003631 10.11 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
11 limbs/digits/tail MP:0005371 10.06 ERBB2 ESR1 MET PAX8 PGR RET
12 no phenotypic analysis MP:0003012 9.97 CDH1 ESR1 HGF KRT19 MET NKX2-1
13 normal MP:0002873 9.96 BRAF CDH1 PAX8 PGR RET ERBB2
14 reproductive system MP:0005389 9.9 BRAF CDH1 ERBB2 ESR1 KRT19 LGALS3
15 respiratory system MP:0005388 9.5 NKX2-1 RET BRAF ERBB2 ESR1 LGALS3
16 skeleton MP:0005390 9.32 BRAF ERBB2 ESR1 KRT19 LGALS3 NKX2-1

Drugs & Therapeutics for Papillary Carcinoma

Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
6
Sunitinib Approved, Investigational Phase 3,Phase 2 341031-54-7, 557795-19-4 5329102
7
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
8
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
13
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
14
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
15
Fluorouracil Approved Phase 3 51-21-8 3385
16
Pancrelipase Approved Phase 3,Early Phase 1 53608-75-6
17
Doxil Approved June 1999 Phase 3,Phase 2 31703
18 Anti-Infective Agents Phase 2, Phase 3, Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Liver Extracts Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 3,Phase 2,Phase 1
24 Antiviral Agents Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Antimitotic Agents Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Antifungal Agents Phase 3,Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
30 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
32 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
33 BCG Vaccine Phase 3,Phase 2
34 Vaccines Phase 3,Phase 2
35 Anti-Infective Agents, Local Phase 2, Phase 3, Phase 1
36 cadexomer iodine Phase 2, Phase 3, Phase 1
37
Iodine Phase 2, Phase 3, Phase 1 7553-56-2 807
38 Micronutrients Phase 2, Phase 3, Phase 1
39 Trace Elements Phase 2, Phase 3, Phase 1
40 Keyhole-limpet hemocyanin Phase 3
41 Topoisomerase Inhibitors Phase 3,Phase 2
42 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2
43 Adjuvants, Anesthesia Phase 3
44 Analgesics Phase 3,Phase 2
45 Analgesics, Opioid Phase 3
46 Anesthetics Phase 3,Phase 2
47 Anesthetics, General Phase 3
48 Anesthetics, Intravenous Phase 3
49 Central Nervous System Depressants Phase 3,Phase 2
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 229)
id Name Status NCT ID Phase
1 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
4 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
5 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
6 Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Completed NCT00006034 Phase 3
7 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3
8 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3
9 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
11 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
12 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
13 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
15 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
16 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Recruiting NCT02449239 Phase 3
17 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
18 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
19 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
20 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3
21 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
22 Savolitinib vs. Sunitinib in MET-driven PRCC Not yet recruiting NCT03091192 Phase 3
23 Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Terminated NCT01310803 Phase 3
24 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Terminated NCT01438112 Phase 2, Phase 3
25 Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer Terminated NCT00042887 Phase 3
26 Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Unknown status NCT00541008 Phase 2
27 Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer Unknown status NCT00786552 Phase 2
28 Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer Unknown status NCT00595088 Phase 2
29 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2
30 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2
31 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
32 Toremifene in Treating Patients With Ovarian Cancer Completed NCT00003865 Phase 2
33 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2
34 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2
35 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Completed NCT00688623 Phase 2
36 Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Completed NCT00867503 Phase 2
37 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
38 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) Completed NCT00726323 Phase 2
39 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2
40 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2
41 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2
42 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
43 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer Completed NCT00542490 Phase 2
44 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2
45 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2
46 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2
47 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2
48 Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT00325507 Phase 2
49 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2
50 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2

Search NIH Clinical Center for Papillary Carcinoma

Cochrane evidence based reviews: carcinoma, papillary

Genetic Tests for Papillary Carcinoma

Anatomical Context for Papillary Carcinoma

MalaCards organs/tissues related to Papillary Carcinoma:

39
Thyroid, Breast, Lymph Node, Ovary, Lung, Kidney, Pancreas

Publications for Papillary Carcinoma

Articles related to Papillary Carcinoma:

(show top 50) (show all 740)
id Title Authors Year
1
Treatment of a giant pulmonary emphysematous cyst with primary bronchoalveolar papillary carcinoma in a Shih Tzu dog. ( 27898174 )
2017
2
Thyroid cancer: Overdiagnosis of papillary carcinoma - who benefits? ( 28059158 )
2017
3
A rare case of papillary carcinoma of thyroid presenting as a lung mass. ( 27728572 )
2016
4
Hypermethylation of the HIC1 promoter and aberrant expression of HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma. ( 27793057 )
2016
5
Case report: Cribriform morular variant of papillary carcinoma. ( 27773102 )
2016
6
Renal cell carcinoma in kidney allografts: histologic types, including biphasic papillary carcinoma. ( 27396934 )
2016
7
Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study. ( 27053333 )
2016
8
Family Screening in Familial Papillary Carcinoma: The Early Detection of Thyroid Disease. ( 27020589 )
2016
9
Hashimoto's thyroiditis and papillary carcinoma in an adolescent girl: A case report. ( 27330783 )
2016
10
An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases. ( 28028333 )
2016
11
Encapsulated papillary carcinoma (EPC) of breast: A clinical, pathological and immunohistochemical analysis of eight cases. ( 27812076 )
2016
12
Intracystic papillary carcinoma of the breast: A SEER database analysis of implications for therapy. ( 27054753 )
2016
13
Application of a cervical low incision in the functional neck dissection of thyroid papillary carcinoma. ( 27073645 )
2016
14
Difference of the Nuclear Green Light Intensity between Papillary Carcinoma Cells Showing Clear Nuclei and Non-neoplastic Follicular Epithelia in Papillary Thyroid Carcinoma. ( 27550048 )
2016
15
Invasive Lobular Carcinoma Mimicking Papillary Carcinoma: A Report of Three Cases. ( 27116593 )
2016
16
CT-detected solitary thyroid calcification: an important imaging feature for papillary carcinoma. ( 27785075 )
2016
17
Follicular Variant of Papillary Carcinoma Arising in Struma Ovarii. ( 27190936 )
2016
18
The risk of hypoparathyroidism after central compartment lymph node dissection in the surgical treatment of pT1, N0 thyroid papillary carcinoma. ( 27212170 )
2016
19
Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma. ( 26715280 )
2016
20
Risk Factors of Lymphnode Metastasis in Patients with Thyroid <br/>Papillary Carcinoma Associated with Graves Disease. ( 27825413 )
2016
21
BONE FUNCTIONING METASTASES REVELING A PAPILLARY CARCINOMA OF THE THYROID. ( 27363445 )
2016
22
Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma. ( 27566169 )
2016
23
Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma. ( 26907966 )
2016
24
The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC). ( 26894377 )
2016
25
An Unusual Solitary Thyroid Nodule with Bloody Follicles: Metastatic Renal Cell Carcinoma Within an Infiltrative Follicular Variant Papillary Carcinoma. ( 26951109 )
2016
26
Activating BRAF Mutations Detected in Mixed HA1rthle Cell Carcinoma and Multifocal Papillary Carcinoma of the Thyroid Gland: Report of an Unusual Case and Review of the Literature. ( 27006301 )
2016
27
Intracystic Papillary Carcinoma of the Breast in a Male Patient. ( 27134706 )
2016
28
Papillary carcinoma of hyoid. ( 27750175 )
2016
29
An Incidental Primary Papillary Carcinoma Arising in a Thyroglossal Duct Cyst: Report of a Rare Finding. ( 27013817 )
2016
30
Clinicopathologic Characteristics of Solid Papillary Carcinoma of the Breast. ( 27438988 )
2016
31
Well differentiated papillary carcinoma of thyroid presenting as metastatic liver mass. ( 26890713 )
2016
32
Dual malignancy in adolescence: A rare case report of metachronous papillary carcinoma of thyroid following dysgerminoma of ovary. ( 27904567 )
2016
33
Renal metastasis from papillary carcinoma thyroid detected by whole body iodine scan: A case report and review of the literature. ( 27385900 )
2016
34
Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma. ( 27698805 )
2016
35
Papillary Carcinoma of Thyroid Gland in a Two-year-old Child. ( 27081805 )
2016
36
Papillary carcinoma in thyroglossal duct cyst: Two case reports and review of the literature. ( 26991228 )
2016
37
Synchronous Papillary Carcinoma of Thyroid and Lung. ( 27236534 )
2016
38
A case of minocycline-induced black thyroid associated with papillary carcinoma. ( 26991226 )
2016
39
Eyelid Metastatic Thyroid Papillary Carcinoma. ( 27239457 )
2016
40
Sparing Surgery for the Successful Treatment of Thyroid Papillary Carcinoma Invading the Trachea: A Case Report. ( 27990114 )
2016
41
Papillary carcinoma of the breast: diagnostic agreement and management implications. ( 27270947 )
2016
42
Can New Ultrasound Signs Help in Identifying Follicular Variant of Papillary Carcinoma of Thyroid? - A Pilot Study. ( 27689170 )
2016
43
Systemic paraneoplastic vasculitis secondary to papillary carcinoma of the thyroid. ( 27416971 )
2016
44
Papillary Carcinoma Within a Thyroglossal Duct Cyst in a 17-Year-Old Child. ( 27054418 )
2016
45
Primary Squamous Cell Carcinoma of Trachea Arising 4 Years After Radioiodine Treatment of Papillary Carcinoma of Thyroid. ( 26828143 )
2016
46
Metastatic gastrinoma in the breast mimicking primary solid papillary carcinoma. ( 27342908 )
2016
47
Solid papillary carcinoma of the breast: A special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. ( 27017244 )
2016
48
Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast? ( 27692774 )
2016
49
Papillary Carcinoma Occurrence in a Thyroglossal Duct Cyst with Synchronous Papillary Thyroid Carcinoma without Cervical Lymph Node Metastasis: Two-Cases Report. ( 25785223 )
2015
50
Does Papillary Carcinoma of Thyroglossal Duct Cyst Develop De Novo? ( 26351606 )
2015

Variations for Papillary Carcinoma

Expression for Papillary Carcinoma

Search GEO for disease gene expression data for Papillary Carcinoma.

Pathways for Papillary Carcinoma

Pathways related to Papillary Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 BRAF CDH1 ERBB2 ESR1 HGF MET
2
Show member pathways
12.54 BRAF CDH1 ERBB2 ESR1 HGF MET
3
Show member pathways
12.26 PAX8 TG TPO TSHR
4 12.15 BRAF CDH1 ERBB2 HGF MET NCOA4
5 11.96 BRAF ERBB2 ESR1 HGF MET
6
Show member pathways
11.71 CDH1 HGF MET
7 11.59 BRAF CDH1 ERBB2
8 11.57 CDH1 ERBB2 MET
9 11.53 BRAF PAX8 TSHR
10 11.5 ERBB2 MET RET
11 11.34 CDH1 HGF MET
12 11.26 CDH1 HGF MET
13 11.16 HGF MET TSHR
14 11.1 CDH1 ERBB2 MET
15 11.06 ERBB2 HGF MET
16 10.48 BRAF CDH1 NCOA4 PAX8 RET
17 10.11 TG TPO TSHR

GO Terms for Papillary Carcinoma

Biological processes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.85 CDH1 ESR1 NCOA4 NKX2-1 PAX8 RET
2 peptidyl-tyrosine phosphorylation GO:0018108 9.71 ERBB2 HGF MET RET
3 MAPK cascade GO:0000165 9.65 BRAF ERBB2 HGF MET RET
4 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.61 ERBB2 HGF MET
5 hormone biosynthetic process GO:0042446 9.51 TG TPO
6 positive chemotaxis GO:0050918 9.5 HGF LGALS3 MET
7 hepatocyte growth factor receptor signaling pathway GO:0048012 9.49 HGF MET
8 positive regulation of adenylate cyclase activity GO:0045762 9.48 CALCA TSHR
9 entry of bacterium into host cell GO:0035635 9.46 CDH1 MET
10 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.16 HGF MET
11 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 PAX8 TSHR
12 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG

Molecular functions related to Papillary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 ERBB2 HGF MET
2 protein tyrosine kinase activity GO:0004713 9.46 ERBB2 HGF MET RET
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 ERBB2 MET RET
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 ERBB2 HGF MET RET
5 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR
6 protein binding GO:0005515 10.27 BRAF CALCA CDH1 ERBB2 ESR1 HGF

Sources for Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....